

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/764,292 01/22/2004		Tadeusz Wieloch	AGYT-041	9165
24353 7590 08/08/2006			EXAMINER	
BOZICEVIC, FIELD & FRANCIS LLP 1900 UNIVERSITY AVENUE			MONTANARI, DAVID A	
SUITE 200		ART UNIT	PAPER NUMBER	
EAST PALO ALTO, CA 94303			1632	

DATE MAILED: 08/08/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)		
	10/764,292	WIELOCH, TADEUSZ		
Office Action Summary	Examiner	Art Unit		
	David Montanari	1632		
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address		
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION B6(a). In no event, however, may a reply be time rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	I. lely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status				
3) Since this application is in condition for allowar closed in accordance with the practice under E	action is non-final. ace except for formal matters, pro			
Disposition of Claims				
4) Claim(s) 1-54 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-54 are subject to restriction and/or experimental objection. Application Papers 9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the objection of the objection objection of the objection of the objection of the objection of	election requirement. r. epted or b) objected to by the Edrawing(s) be held in abeyance. See	e 37 CFR 1.85(a).		
11) The oath or declaration is objected to by the Ex	• • • • • • • • • • • • • • • • • • • •	• •		
Priority under 35 U.S.C. § 119				
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:			

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-16, drawn to a method of generating an animal model exhibiting a pathological condition of Alzheimer's disease, classified in class 800, subclass 21.
- II. Claims 17-39, drawn to a method of developing a modulator of pathogenesis of Alzheimer's disease, classified in class 800, subclass 3.
- III. Claims 40-54, drawn to a method of developing a modulator of an Alzheimer's disease-associated gene or protein, classified in class 435, subclass 4.

Groups I and II are distinct. Group I is drawn to method of generating an Alzheimer's animal model. Group II is drawn to method of developing a modulator of Alzheimer's disease pathogenesis using the animal generated by the method of Group I. The method of generating and animal model would require materially distinct and separate protocols from the method of developing a modulator for Alzheimer's disease in an animal model Alzheimer's disease.

Groups I and III are distinct. Group I is drawn to method of generating an Alzheimer's animal model. Group III is drawn to a method of developing a modulator of an Alzheimer's disease associated gene or protein in an isolated sample from the animal generated by the method of Group I. The method of generating and animal model would require materially distinct and separate protocols from the method of developing a modulator for Alzheimer's disease

Art Unit: 1632

associated gene or protein.

Groups II and III are distinct. Group II is drawn to method of developing a modulator of Alzheimer's disease pathogenesis using the animal generated by the method of Group I. Group III is drawn to a method of developing a modulator of an Alzheimer's disease associated gene or protein in an isolated sample from the animal generated by the method of Group I. The methods of Group II and III require materially distinct and separate protocols because the method of Group II is done in the animal, whereas the method of Group III is done in an isolated sample the animal.

Based upon the restriction requirement above an undo search burden would be required to search

all of the distinct groups.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined.

See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and the search required is different among each group, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Montanari whose telephone number is 1-571-272-3108. The examiner can normally be reached on M-F 9-5:30.

Application/Control Number: 10/764,292

Art Unit: 1632

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on 1-571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 1-571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David A. Montanari, Ph.D.

DAVE TRONG NGUYEN
CLIPERVISORY PATENT EXAMINER

Page 5